STOCK TITAN

CYAD - CYAD STOCK NEWS

Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.

Celyad Oncology (symbol: CYAD) is a clinical-stage biopharmaceutical company founded in 2007. The company is renowned for its expertise in cell-based therapies, particularly in taking them from the initial research phase to Phase III clinical trials. Celyad boasts robust manufacturing and logistical infrastructure designed to support the development of complex cell-based products.

Celyad's business model is rooted in strategic partnerships with esteemed research institutions such as Dartmouth College. These collaborations are instrumental in advancing their innovative programs from bench research to commercial applications.

One of the company's major focus areas is immuno-oncology, where it is pioneering the development of natural killer receptor T-cells (NKR-T cells) aimed at treating cancer. This unique therapeutic approach has shown promise in targeting and potentially destroying a wide variety of tumor types, positioning Celyad at the forefront of cancer treatment innovation.

Listed on Euronext Brussels, Euronext Paris, and NASDAQ under the ticker symbol CYAD, Celyad continues to gain recognition for its groundbreaking work in the biotech industry. The financial condition of the company is robust, with ongoing projects that underscore its commitment to transforming cancer care. Recent achievements and current projects reflect a steadfast dedication to clinical excellence and innovation.

Rhea-AI Summary

Celyad Oncology has announced the sale of its Good Manufacturing Practice (GMP) cell therapy manufacturing operations to Cellistic for €6 million. The facility, located in Mont-Saint-Guibert, Belgium, comes with an experienced team of over 30 personnel. The transaction aims to streamline Celyad's focus on allogeneic therapies while leveraging Cellistic's expertise in iPSC-based cell therapies. The deal is anticipated to close in Q4 2022, providing Celyad with resources to continue its clinical programs until 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Celyad Oncology announced ongoing enrollment in its Phase 1 dose-escalation trial for CYAD-211, targeting relapsed/refractory multiple myeloma. The FDA lifted the hold on CYAD-101 for metastatic colorectal cancer. The company reported a net loss of €14.1 million for H1 2022, an improvement from €14.9 million in H1 2021. Cash reserves stand at €14.4 million. Research and development expenses rose to €10.5 million due to increased IP costs. Celyad aims to enhance partnerships leveraging its extensive CAR T technology IP portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Celyad Oncology (CYAD) announced the FDA has lifted the clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, enabling the continuation of its investigation into allogeneic NKG2D CAR T cell therapy combined with KEYTRUDA for refractory metastatic colorectal cancer. The trial had been paused due to safety concerns following reports of fatalities. Celyad remains optimistic about the potential of CYAD-101 and its proprietary TIM technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced plans to report its first half 2022 financial and operating results on August 5, 2022. Following this release, management will host a conference call at 2 p.m. CEST to discuss the results and updates on recent progress and milestones.

The company is focused on CAR T therapies for cancer and has a pipeline of candidates for treating hematological malignancies and solid tumors. Detailed insights on its financial condition and ongoing trials, including the CYAD-101-002 trial, will be provided during the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Celyad Oncology SA (NASDAQ:CYAD) announced the appointment of Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Windels has been on the board since May 2018 and has extensive experience in the life sciences sector. She replaces Michel Lussier, who becomes the Interim Chief Executive Officer following the resignation of Filippo Petti. Petti will assist during the transition until July 31, 2022. The company's strategy focuses on developing innovative CAR T therapies for cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that as of May 25, 2022, 350 registered shares will benefit from double voting rights. This change increases the total number of voting rights to 24,962,331. The company disclosed this in compliance with Belgian regulations regarding major shareholdings. Key figures include a total share capital of €78,584,224.33, with 20,225,581 shares having single voting rights and 2,368,375 shares having double voting rights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Celyad Oncology SA (Brussels:CYAD) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will present virtually, with on-demand access starting at 7:00 a.m. EST on May 24, 2022. Celyad Oncology focuses on developing CAR T therapies for cancer, including both allogeneic and autologous candidates targeting hematological malignancies and solid tumors. The company, founded in 2007, received funding from the Walloon Region of Belgium to support its programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

The financial update from Celyad Oncology (CYAD) highlights a cash position of €20.5 million ($22.9 million) and a net cash burn of €9.5 million ($10.6 million) for Q1 2022. The Phase 1 IMMUNICY-1 trial for CYAD-211 continues to enroll patients to evaluate its effectiveness against relapsed/refractory multiple myeloma. However, the CYAD-101-002 Phase 1b trial remains on clinical hold due to safety concerns, following reported fatalities. The company plans to release additional data on CYAD-211 in H2 2022 and expects its cash reserves to last until mid-2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Celyad Oncology SA (NASDAQ: CYAD) provided an update on its business and financial results for Q1 2022. The Phase 1 IMMUNICY-1 trial for the allogeneic CAR T candidate CYAD-211 for relapsed/refractory multiple myeloma (MM) is ongoing, with additional data expected in H2 2022. However, the CYAD-101-002 Phase 1b trial remains on clinical hold after two fatalities were reported. As of March 31, 2022, the company had €20.6 million in cash, with a net cash burn of €9.4 million during the quarter, sufficient to fund operations until mid-2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the market cap of CYAD (CYAD)?

The market cap of CYAD (CYAD) is approximately 14.2M.

What does Celyad Oncology specialize in?

Celyad Oncology specializes in developing cell-based therapies, particularly in immuno-oncology, using natural killer receptor T-cells (NKR-T cells) for cancer treatment.

When was Celyad Oncology founded?

Celyad Oncology was founded in 2007.

On which stock exchanges is Celyad listed?

Celyad is listed on Euronext Brussels, Euronext Paris, and NASDAQ.

What is the company's ticker symbol?

The ticker symbol for Celyad Oncology is CYAD.

Who are Celyad's key research partners?

Celyad collaborates with prominent research institutions such as Dartmouth College.

What are natural killer receptor T-cells (NKR-T cells)?

NKR-T cells are a type of cell therapy being developed by Celyad for targeting and destroying various tumor types in cancer treatment.

What is Celyad's business model?

Celyad's business model focuses on partnerships with research institutions to advance cell-based therapy programs from bench research to commercial applications.

What are some recent achievements of Celyad Oncology?

Celyad has recently made significant progress in its clinical programs in immuno-oncology and is advancing its NKR-T cell therapies through various stages of clinical trials.

What is the status of Celyad's financial condition?

Celyad maintains a robust financial condition, supporting ongoing projects and development efforts in cell-based cancer therapies.

How can I stay updated on Celyad's latest news?

You can stay updated on Celyad's latest news by following their official announcements and news releases on their website or financial news platforms.

CYAD

Nasdaq:CYAD

CYAD Rankings

CYAD Stock Data

14.24M
13.58M
0.05%
29.15%
0.58%
Biotechnology
Healthcare
Link
Belgium
Mont-Saint-Guibert